Literature DB >> 22300494

Banff 2011 Meeting report: new concepts in antibody-mediated rejection.

M Mengel1, B Sis, M Haas, R B Colvin, P F Halloran, L C Racusen, K Solez, L Cendales, A J Demetris, C B Drachenberg, C F Farver, E R Rodriguez, W D Wallace, D Glotz.   

Abstract

The 11th Banff meeting was held in Paris, France, from June 5 to 10, 2011, with a focus on refining diagnostic criteria for antibody-mediated rejection (ABMR). The major outcome was the acknowledgment of C4d-negative ABMR in kidney transplants. Diagnostic criteria for ABMR have also been revisited in other types of transplants. It was recognized that ABMR is associated with heterogeneous phenotypes even within the same type of transplant. This highlights the necessity of further refining the respective diagnostic criteria, and is of particular significance for the design of randomized clinical trials. A reliable phenotyping will allow for definition of robust end-points. To address this unmet need and to allow for an evidence-based refinement of the Banff classification, Banff Working Groups presented multicenter data regarding the reproducibility of features relevant to the diagnosis of ABMR. However, the consensus was that more data are necessary and further Banff Working Group activities were initiated. A new Banff working group was created to define diagnostic criteria for ABMR in kidneys independent of C4d. Results are expected to be presented at the 12th Banff meeting to be held in 2013 in Brazil. No change to the Banff classification occurred in 2011. © copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22300494      PMCID: PMC3728651          DOI: 10.1111/j.1600-6143.2011.03926.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  41 in total

Review 1.  Transplant glomerulopathy.

Authors:  F G Cosio; J M Gloor; S Sethi; M D Stegall
Journal:  Am J Transplant       Date:  2008-03       Impact factor: 8.086

2.  The Banff 2007 working classification of skin-containing composite tissue allograft pathology.

Authors:  L C Cendales; J Kanitakis; S Schneeberger; C Burns; P Ruiz; L Landin; M Remmelink; C W Hewitt; T Landgren; B Lyons; C B Drachenberg; K Solez; A D Kirk; D E Kleiner; L Racusen
Journal:  Am J Transplant       Date:  2008-07       Impact factor: 8.086

3.  Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy.

Authors:  R Snanoudj; V Royal; C Elie; M Rabant; C Girardin; E Morelon; H Kreis; J-C Fournet; L-H Noël; C Legendre
Journal:  Am J Transplant       Date:  2011-08-30       Impact factor: 8.086

4.  Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients.

Authors:  M D Stegall; T Diwan; S Raghavaiah; L D Cornell; J Burns; P G Dean; F G Cosio; M J Gandhi; W Kremers; J M Gloor
Journal:  Am J Transplant       Date:  2011-09-22       Impact factor: 8.086

5.  NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection.

Authors:  L G Hidalgo; B Sis; J Sellares; P M Campbell; M Mengel; G Einecke; J Chang; P F Halloran
Journal:  Am J Transplant       Date:  2010-08       Impact factor: 8.086

6.  Transplant glomerulopathy: ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies.

Authors:  M D Wavamunno; P J O'Connell; M Vitalone; C L-S Fung; R D M Allen; J R Chapman; B J Nankivell
Journal:  Am J Transplant       Date:  2007-10-06       Impact factor: 8.086

7.  Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation.

Authors:  James M Gloor; Steven DeGoey; Nancy Ploeger; Howard Gebel; Robert Bray; S Breanndan Moore; Patrick G Dean; Mark D Stegall
Journal:  Transplantation       Date:  2004-07-27       Impact factor: 4.939

8.  The effect of antithymocyte globulin on anti-human leukocyte antigen antibody detection assays.

Authors:  James M Gloor; S Breanndan Moore; Brittany A Schneider; Steven R Degoey; Mark D Stegall
Journal:  Transplantation       Date:  2007-07-27       Impact factor: 4.939

Review 9.  Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients.

Authors:  S C Jordan; A A Vo; A Peng; M Toyoda; D Tyan
Journal:  Am J Transplant       Date:  2006-03       Impact factor: 8.086

10.  Identifying specific causes of kidney allograft loss.

Authors:  Z M El-Zoghby; M D Stegall; D J Lager; W K Kremers; H Amer; J M Gloor; F G Cosio
Journal:  Am J Transplant       Date:  2008-02-03       Impact factor: 8.086

View more
  109 in total

Review 1.  The impact of donor-specific anti-HLA antibodies on late kidney allograft failure.

Authors:  Alexandre Loupy; Gary S Hill; Stanley C Jordan
Journal:  Nat Rev Nephrol       Date:  2012-04-17       Impact factor: 28.314

Review 2.  B Cells, Antibodies, and More.

Authors:  William Hoffman; Fadi G Lakkis; Geetha Chalasani
Journal:  Clin J Am Soc Nephrol       Date:  2015-12-23       Impact factor: 8.237

Review 3.  Histopathological diagnosis of acute and chronic rejection in pediatric kidney transplantation.

Authors:  Verena Bröcker; Michael Mengel
Journal:  Pediatr Nephrol       Date:  2013-10-19       Impact factor: 3.714

Review 4.  Effector mechanisms of rejection.

Authors:  Aurélie Moreau; Emilie Varey; Ignacio Anegon; Maria-Cristina Cuturi
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

Review 5.  Translational implications of endothelial cell dysfunction in association with chronic allograft rejection.

Authors:  Sarah Bruneau; Johannes Wedel; Fadi Fakhouri; Hironao Nakayama; Leo Boneschansker; Daniel Irimia; Kevin P Daly; David M Briscoe
Journal:  Pediatr Nephrol       Date:  2015-04-24       Impact factor: 3.714

6.  Monocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcγRIIa polymorphisms.

Authors:  N M Valenzuela; K R Trinh; A Mulder; S L Morrison; E F Reed
Journal:  Am J Transplant       Date:  2015-02-03       Impact factor: 8.086

7.  Delayed graft function and the risk of acute rejection in the modern era of kidney transplantation.

Authors:  W Kelly Wu; Olusegun Famure; Yanhong Li; S Joseph Kim
Journal:  Kidney Int       Date:  2015-06-24       Impact factor: 10.612

8.  Endothelial cell antibodies associated with novel targets and increased rejection.

Authors:  Annette M Jackson; Tara K Sigdel; Marianne Delville; Szu-Chuan Hsieh; Hong Dai; Serena Bagnasco; Robert A Montgomery; Minnie M Sarwal
Journal:  J Am Soc Nephrol       Date:  2014-11-07       Impact factor: 10.121

Review 9.  Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation.

Authors:  Antonio Cuadrado; David San Segundo; Marcos López-Hoyos; Javier Crespo; Emilio Fábrega
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

10.  Banff Initiative for Quality Assurance in Transplantation (BIFQUIT): reproducibility of polyomavirus immunohistochemistry in kidney allografts.

Authors:  B Adam; P Randhawa; S Chan; G Zeng; H Regele; Y B Kushner; R B Colvin; J Reeve; M Mengel
Journal:  Am J Transplant       Date:  2014-08-04       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.